Idera Pharmaceuticals Inc news

   Watch this stock
Showing stories 1 - 10 of about 83   

Articles published

IDRA 1.67 +0.07 (4.37%)
price chart
Why Idera Pharmaceuticals Inc. Shares Dropped 36% in 2015
What: Shareholders of Idera Pharmaceuticals (NASDAQ:IDRA), a clinical-stage biopharmaceutical company focused on cancer and other rare diseases, had a rough 2015.
Stock Up Nicely This Week: Idera Pharmaceuticals, Inc. (NASDAQ:IDRA)
Investors Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) are heading into the weekend on a positive note as the stock provided some gains this week moving 5.03% over the past 5 trading days.
Idera Pharmaceuticals, Inc. (NASDAQ:IDRA)'s Basic Consolidated EPS Came ...  Equities Focus
Idera Pharmaceuticals Inc (NASDAQ:IDRA) Ready For A Comeback
2015 was a rough year for shareholders of Idera Pharmaceuticals Inc (NASDAQ:IDRA). While the company made considerable progress, shares were on a downtrend for all of 2015.
Idera Pharmaceuticals, Inc. Stock Momentum at Critical Inflection Point
This is a momentum stock rating analysis for Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) . The company has a three bull momentum rating which indicates an inflection point.
Idera Pharmaceuticals: Is The Writing On The Wall?
Idera Pharmaceuticals has shown recent successes in advancing their technology for treatment of many life threatening diseases, which makes it an attractive investment.
Idera Pharmaceuticals: A Star In The Making (IDRA)
Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) is a biotechnology company engaged in discovering and developing Toll-Like Receptors (TLRs) antagonists, novel-synthetic DNA and RNA based drug candidates.
Related articles »  
Company Update (NASDAQ:IDRA): Idera Pharmaceuticals Inc to Collaborate With ...
Idera Pharmaceuticals Inc (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with cancer and rare diseases, today announced it has entered into an exclusive worldwide collaboration ...
Idera to Collaborate With GSK to Identify 3rd Generation Antisense Molecules ...  GlobeNewswire (press release)
While Big Pharma gets bigger, local biotechs innovate  The Boston Globe
Biotech Stocks Worth Chasing: Idera Pharmaceuticals, Inc. (IDRA), Intrexon ...
Idera Pharmaceuticals, Inc. (IDRA) ended last trading session with a change of 8.33 percent. It trades at an average volume of 892.81K shares versus 2.13M shares recorded at the end of last trading session.
Why Idera Pharmaceuticals Inc. Shares Vaulted Higher
What: Shares of Idera Pharmaceuticals (NASDAQ:IDRA), a clinical-stage biopharmaceutical company focused on developing therapies to treat cancer and other rare diseases, vaulted higher by as much as 15% during Monday's trading session after providing ...
Idera Pharmaceuticals Provides Development Update on IMO-9200, an Antagonist ...  GlobeNewswire (press release)
Idera Pharma (IDRA) Announces Top Line Results for Phase 1 Study of IMO-9200  StreetInsider.com
Stock Update (NASDAQ:IDRA): Idera Pharmaceuticals Inc Presents Preclinical ...
Idera Pharmaceuticals Inc (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with cancer and rare diseases, today announced new preclinical data demonstrating enhanced systemic ...
Idera Presents Preclinical Data Demonstrating Enhanced Systemic Anti-Tumor ...  GlobeNewswire (press release)